Moxifloxacin

Generic Name: Moxifloxacin

Brand Names: Avelox, Moxeza, Vigamox

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₄FN_₃O_₄

CAS Number: 151096-09-2

Unique Ingredient Identifier: U188XYD42P

Background: Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication: For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections

Clinical Trials

Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia

Phase 2

Completed

Conditions: Tuberculosis

First Posted Date: 2006-03-23

Last Posted Date: 2020-11-12

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 23

Registration Number: NCT00306319

Locations: 🇮🇩
Rumah Sakit Hasan Sadikin (RSHS), Bandung, Indonesia

Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Other: Placebo
Drug: Rotigotine
Drug: Moxifloxacin infusion
Other: Placebo infusion

First Posted Date: 2006-02-15

Last Posted Date: 2014-10-27

Lead Sponsor: UCB Pharma

Target Recruit Count: 130

Registration Number: NCT00292227

Locations: 🇿🇦
Farmovs-Parexel (Pty) Ltd, Bloemfontein, South Africa
🇿🇦
Qdot, a division of Parexel International DA (Pty) Ltd., George, South Africa

A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2005-11-23

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT00257452

Locations: 🇩🇪
Humanpharmakologisches Zentrum, Ingelheim/Rhein, Germany

A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)

Phase 3

Completed

Conditions: Chronic Bronchitis

Interventions: Other: Azithromycin SR Placebo
Other: Moxifloxacin Placebo
Drug: Azithromycin SR
Drug: Moxifloxacin

First Posted Date: 2005-11-16

Last Posted Date: 2009-11-11

Lead Sponsor: Pfizer

Target Recruit Count: 398

Registration Number: NCT00254566

Locations: 🇹🇭
Pfizer Investigational Site, Khon Kaen, Thailand

Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers

Phase 1

Completed

Conditions: Human Experimentation (Human Volunteers)

First Posted Date: 2005-09-20

Last Posted Date: 2005-12-15

Lead Sponsor: J. Uriach and Company

Target Recruit Count: 160

Registration Number: NCT00199225

Locations: 🇪🇸
Centre de Investigació de Medicaments-Intitut de Recerca-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade

Phase 1

Completed

Conditions: Patients With Pace Makers But no Evidence of Ischemic Heart Disease

First Posted Date: 2005-09-15

Last Posted Date: 2006-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00174512

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Isoniazid
Drug: Moxifloxacin

First Posted Date: 2005-09-14

Last Posted Date: 2011-06-08

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 72

Registration Number: NCT00164463

Locations: 🇺🇬
Makerere University Medical School, Kampala, Uganda
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 5 locations

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

Phase 1

Completed

Conditions: Hypertension

First Posted Date: 2005-09-12

Last Posted Date: 2005-09-12

Lead Sponsor: Mylan Bertek Pharmaceuticals

Target Recruit Count: 260

Registration Number: NCT00158093

Locations: 🇺🇸
SFBC International, Inc., Miami, Florida, United States

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)
Drug: isoniazid

First Posted Date: 2005-09-05

Last Posted Date: 2011-08-03

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 433

Registration Number: NCT00144417

Locations: 🇺🇸
Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States
🇺🇸
University of Southern California Medical Center, Los Angeles, California, United States
🇺🇸
University of California at San Diego, San Diego, California, United States

and more 23 locations

TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment

Phase 2

Completed

Conditions: Tuberculosis, Pulmonary

First Posted Date: 2005-09-01

Last Posted Date: 2007-03-19

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 350

Registration Number: NCT00140309

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇬
Makerere University Medical School, Kampala, Uganda
🇺🇸
Columbia University, New York, New York, United States

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy